Compass Therapeutics, Inc. (CMPX) Stock Price & Analysis
Compass Therapeutics, Inc. (CMPX) closed at USD 0.9 on Thursday, October 15, 2026, up 2.01% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.88; the Oct 15, 2026 session ranged USD 0.85–0.9 on volume of 3,328,649 shares. Market capitalization is $161.48M, with a 52-week range of USD 0.82–6.88 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CMPX.md
Key facts (CMPX)
- Analysts: Buy (mean 2.07 on a 1–5 scale) (15 analysts), mean target USD 5.45 (range 1–12).
- Total return with dividends: 1Y -80.2% vs S&P 500 +18.1%; 5Y -72.1% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.13, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CMPX)
| USD | FY2021 | FY2022 | FY2024 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0K | $850K | $0K | — |
| Operating income | -$81.9M | -$41.7M | -$50.4M | -$56.6M | -$72.8M | -$81.1M |
| Net income | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M | -$73.4M |
| EPS (diluted) | -$1.31 | — | — | — | — | — |
| Free cash flow | -$21.2M | -$34.3M | -$40.6M | -$44.9M | -$49.2M | -$56.4M |
| Operating margin | — | — | — | -6661.8% | — | — |
| Net margin | — | — | — | -5808.8% | — | — |
| Revenue growth | — | — | — | — | -100.0% | — |
| Cash + short-term investments | $145M | $187M | $152M | $127M | $209M | — |
| Total debt | $0K | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CMPX)
P/B 1.0x · FCF yield -34.91% · Earnings yield -45.48%
Analysts (CMPX)
Consensus Buy (mean 2.07 on a 1–5 scale), 15 analysts; mean target USD 5.45 (low 1, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | Craig-Hallum | Target lowered | Buy | $15 → $8 |
| 2026-09-23 | Citizens | Target lowered | Market Outperform | $10 → $4 |
| 2026-09-23 | Guggenheim | Target lowered | Buy | $8 → $4 |
| 2026-09-23 | Wedbush | Downgrade | Outperform → Neutral | $5 → $1 |
| 2026-09-23 | HC Wainwright & Co. | Target lowered | Buy | $24 → $12 |
| 2026-08-07 | Piper Sandler | Target raised | Overweight | $4 → $6 |
Total return (dividends reinvested) (CMPX)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -80.2% | -72.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -80.3% | -22.5% |
| Volatility (annualized) | 127.4% | 91.2% |
| Max drawdown | -87.2% (Feb 2026→Oct 2026) | -86.9% (Feb 2026→Sep 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 0.9 |
|---|---|
| Change | ▲ 2.01% (up) |
| Previous Close | USD 0.88 |
| Open | USD 0.86 |
| Day Range | USD 0.85 – 0.9 |
| 52-Week Range | USD 0.82 – 6.88 |
| Volume | 3,328,649 shares |
| Market Cap | $161.48M |
| Exchange | NCM |
Technical Analysis (CMPX)
Nexqual's technical model rates CMPX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 22.26 (oversold) |
| vs SMA50 | Below (USD 1.79) |
| MACD | -0.26 (negative) |
Analyst Ratings (CMPX)
Wall Street analysts rate CMPX "Buy" based on 15 analysts, with a mean price target of USD 5.45 (range USD 1–12), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 5.45 |
| High Target | USD 12 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 12 / 3 / 0 |
Earnings (CMPX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.11 ▼ miss |
| 2026-03-31 | USD -0.1 vs est -0.1 ▲ beat |
| 2025-12-31 | USD -0.09 vs est -0.09 ▼ miss |
| 2025-09-30 | USD -0.08 vs est -0.13 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (CMPX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -56.66% |
| Debt / Equity | 0.06 |
| Current Ratio | 11.22 |
| Total Cash | $179.88M |
| Total Debt | $9.63M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (CMPX)
Nexqual rates Compass Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $180M cash vs $10M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$49M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -57%, ROA -33.0% |
Ownership (CMPX)
| Insider Ownership | +12.47% |
|---|---|
| Institutional Ownership | +88.51% |
| Shares Outstanding | 180.09M |
| Float | 132.42M |
| Short % of Float | +26.79% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (CMPX)
Compass Therapeutics, Inc. is led by Thomas J. Schuetz (age 64), CEO & Vice Chairman, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO & Vice Chairman | Thomas J. Schuetz (age 64) |
|---|---|
| Chief Financial Officer | Barry Shin (age 53) |
| Chief Scientific Officer | Bing Gong (age 49) |
Major Backers & Investors (CMPX)
Notable institutional backers of Compass Therapeutics, Inc. include Tang Capital Management, LLC, Orbimed Advisors LLC., Montanova Capital LLC, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Tang Capital Management, LLC | 34.52% |
| Orbimed Advisors LLC. | 29.2% |
| Montanova Capital LLC | 27.05% |
| Enavate Sciences Gp, LLC | 14.94% |
| Vivo Capital, LLC | 14.88% |
| Palo Alto Investors Lp | 11.19% |
| Millennium Management | 9.04% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 30.48% |
| State Street | 28.32% |
| Vanguard Group | 26.56% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
From Compass Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- We also rely on trade secrets and know-how relating to our proprietary technology platform, on continuing technological innovation and on in-licensing opportunities to develop, strengthen and maintain the strength of our position in the field of antibody therapeutics that may be important for the development of our business.
- For example, we file U.S. and selected foreign patent applications related to our proprietary technology, inventions, and improvements that are important to the development of our business.
- We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors.
- The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources.   Review and Approval for Licensing Biologics in the United States   In the United States, the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act ("FDCA"), and the Public Health Service Act ("PHSA"), and their implementing regulations.
Partnerships
- As a result of the TRIGR acquisition, we have assumed all the rights and obligations of the TRIGR License Agreement.   CTX-471 (CD137 agonist antibody)   We entered into an amended and restated collaboration agreement with Adimab, LLC ("Adimab"), dated February 11, 2015.
- In addition, ABL Bio is eligible to receive up to $96 million of development and regulatory milestone payments, up to $303 million of commercial milestone payments and tiered single-digit royalties on net sales of tovecimig in oncology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt